Feiyang Ma

Featured in: Favicon

nature.com Favicon

arxiv.org

mdpi.com

acs.org

science.org Favicon

cell.com

jci.org

tmc.edu

jimmunol.org Favicon

biorxiv.org + 1 more

Articles

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial - Nature Communications

Nov 13, 2024 | nature.com | Vera Adema |Kelly S. Chien |Sanam Loghavi |Feiyang Ma |Guillermo Montalban-Bravo |Xuelin Huang | +1 more

AbstractIn myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells’ (HSPCs’) aberrant differentiation towards the myeloid lineage at the expense of erythropoiesis.
The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial - Nature Communications

Nov 13, 2024 | nature.com | Vera Adema |Kelly S. Chien |Sanam Loghavi |Feiyang Ma |Guillermo Montalban-Bravo |Xuelin Huang | +1 more

AbstractIn myelodysplastic syndromes (MDS), the IL-1β pathway is upregulated, and previous studies using mouse models of founder MDS mutations demonstrated that it enhances hematopoietic stem and progenitor cells’ (HSPCs’) aberrant differentiation towards the myeloid lineage at the expense of erythropoiesis.
Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapies - Nature Nanotechnology

Sep 23, 2024 | nature.com | Enbo Zhu |Jiaji Yu |Yan-Ruide Li |Feiyang Ma |Yang Liu |James Brown | +2 more

AbstractChimeric antigen receptor (CAR)-engineered T cells represent a front-line therapy for cancers. However, the current CAR T cell manufacturing protocols do not adequately reproduce immunological synapse formation. Here, in response to this limitation, we have developed a flexible graphene oxide antigen-presenting platform (GO-APP) that anchors antibodies onto graphene oxide.
Hematopoietic Stem Cells With Granulo-Monocytic Differentiation State Overcome Venetoclax Sensitivity in Patients With Myelodysplastic Syndromes

Aug 21, 2024 | digitalcommons.library.tmc.edu | Juan José Rodríguez-Sevilla |Irene Ganan-Gomez |Feiyang Ma |Kelly S. Chien

The molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetoclax after an initial response remain to be elucidated.
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes - Nature Communications

Mar 18, 2024 | nature.com | Feiyang Ma |Kelly S. Chien |Sanam Loghavi |Guillermo Montalban-Bravo |Vera Adema |Rashmi Kanagal-Shamanna | +2 more

AbstractThe molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetoclax after an initial response remain to be elucidated.
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma - Nature Communications

Feb 7, 2024 | nature.com | Feiyang Ma |Natalia Baran |Jintan Liu |Ken Furudate |Paola Storti |Irene Ganan-Gomez | +10 more

AbstractDNA damage resistance is a major barrier to effective DNA-damaging therapy in multiple myeloma (MM). To discover mechanisms through which MM cells overcome DNA damage, we investigate how MM cells become resistant to antisense oligonucleotide (ASO) therapy targeting Interleukin enhancer binding factor 2 (ILF2), a DNA damage regulator that is overexpressed in 70% of MM patients whose disease has progressed after standard therapies have failed.
Key patient demographics shape innate immune topography in noncritical hypoxic COVID-19 pneumonia

Aug 22, 2023 | insight.jci.org | JCI Insight |Allison C. Billi |Rachael Wasikowski |Feiyang Ma

AbstractRisk of severe disease and death due to COVID-19 is increased in certain patient demographic groups, including those of advanced age, male sex, and obese body mass index. Investigations of the biological variations that contribute to this risk have been hampered by heterogeneous severity, with immunologic features of critical disease potentially obscuring differences between risk groups.
Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis

Jul 20, 2023 | insight.jci.org | JCI Insight |Enze Xing |Feiyang Ma |Rachael Wasikowski

AbstractPansclerotic morphea (PSM) is a rare, devastating disease characterized by extensive soft tissue fibrosis, secondary contractions, and significant morbidity. PSM pathogenesis is unknown, and aggressive immunosuppressive treatments rarely slow disease progression.
Differentiation of IL-26+ TH17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis - Nature Communications

Jun 30, 2023 | nature.com | François Kuonen |Nadine Fournier |Feiyang Ma |Johann E. Gudjonsson |Lennart M. Roesner |Curdin Conrad | +2 more

AbstractInterleukin (IL)-26 is a TH17 cytokine with known antimicrobial and pro-inflammatory functions. However, the precise role of IL-26 in the context of pathogenic TH17 responses is unknown. Here we identify a population of blood TH17 intermediates that produce high levels of IL-26 and differentiate into IL-17A-producing TH17 cells upon TGF-β1 exposure. By combining single cell RNA sequencing, TCR sequencing and spatial transcriptomics we show that this process occurs in psoriatic skin.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Feiyang Ma

Articles

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial - Nature Communications

The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial - Nature Communications

Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapies - Nature Nanotechnology

Hematopoietic Stem Cells With Granulo-Monocytic Differentiation State Overcome Venetoclax Sensitivity in Patients With Myelodysplastic Syndromes

Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes - Nature Communications

Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma - Nature Communications

Key patient demographics shape innate immune topography in noncritical hypoxic COVID-19 pneumonia

Pansclerotic morphea is characterized by IFN-γ responses priming dendritic cell fibroblast crosstalk to promote fibrosis

Differentiation of IL-26+ TH17 intermediates into IL-17A producers via epithelial crosstalk in psoriasis - Nature Communications

Contact details

Emails

Socials & Sites